Drug intelligence / Profile preview

Eupenta

Development stage: Unknown
Lead developer: LG Chem
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Eupenta is a fully liquid pentavalent combination vaccine developed and manufactured by LG Chem. It is designed for the active primary immunization of infants from 6 weeks of age against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) infections. The formulation includes diphtheria toxoid, tetanus toxoid, inactivated whole-cell pertussis suspension, recombinant hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide conjugated to tetanus toxoid. Eupenta received WHO prequalification in 2016 and has been a major supplier for global immunization programs through UNICEF, reaching millions of infants worldwide.

Brand names: Eupenta
Other names: Eupenta Inj.DTP-HepB-Hib vaccine

Targets

HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)

Beyond the preview

Go deeper on Eupenta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eupenta.

Explore the full profile